Citius Oncology Stock (NASDAQ:CTOR)
Previous Close
$1.13
52W Range
$0.55 - $6.19
50D Avg
$1.50
200D Avg
$1.53
Market Cap
$93.54M
Avg Vol (3M)
$373.59K
Beta
2.99
Div Yield
-
CTOR Company Profile
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Industry
Drug Manufacturers - General
Sector
Healthcare
Exchange
NASDAQ
ADR
-
Country
US
Employees
-
IPO Date
-
Website
-